---
title: "IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | IDYA Stock News"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/271501365.md"
description: "IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:45 PM PT. CEO Yujiro S. Hata will present, followed by a Q&A session hosted by J.P. Morgan's Anupam Rama. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA focuses on precision medicine for oncology, developing targeted therapies for cancer."
datetime: "2026-01-05T03:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271501365.md)
  - [en](https://longbridge.com/en/news/271501365.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271501365.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/271501365.md) | [English](https://longbridge.com/en/news/271501365.md)


# IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | IDYA Stock News

, /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare Conference.

44th Annual J.P. Morgan Healthcare Conference  
Monday, January 12th, 2026, at 3:45 PM PT (6:45 PM ET)

-   Presentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan

A live audio webcast of the presentation and Q&A session will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.

**About IDEAYA Biosciences**

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

**Forward-Looking Statements**

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.

**Investor and Media Contact  
**IDEAYA Biosciences  
Joshua Bleharski, Ph.D.  
Chief Financial Officer  
investor@ideayabio.com

SOURCE IDEAYA Biosciences, Inc.

### 相關股票

- [Ideaya Biosciences (IDYA.US)](https://longbridge.com/zh-HK/quote/IDYA.US.md)

## 相關資訊與研究

- [IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA Stock News](https://longbridge.com/zh-HK/news/280767304.md)
- [A Look At IDEAYA Biosciences (IDYA) Valuation After Early IDE849 And IDE161 Combination Trial Activity](https://longbridge.com/zh-HK/news/281427519.md)
- [Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness](https://longbridge.com/zh-HK/news/280264225.md)
- [IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs | IDYA Stock News](https://longbridge.com/zh-HK/news/279571290.md)
- [Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing](https://longbridge.com/zh-HK/news/277589490.md)